Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 10, 2000 - Issue 4
Submit an article Journal homepage
34
Views
13
CrossRef citations to date
0
Altmetric
Review

Regulators of the anaphylatoxin C5a

Stephen M Taylor Department of Physiology and Pharmacology and Centre for Drug Design and Development, University of Queensland, Brisbane, Qld 4072, Australia. [email protected]
&
David P Fairlie Department of Physiology and Pharmacology and Centre for Drug Design and Development, University of Queensland, Brisbane, Qld 4072, Australia. [email protected]
Pages 449-458 | Published online: 25 Feb 2005

Bibliography

  • MAKRIDES SC: Therapeutic inhibition of the comple- ment, system. Pharmacol. Rev. (1998) 50:59–87.
  • ••A recent comprehensive review of the field.
  • GERARD NP, GERARD C: The chemotactic receptor for human C5a anaphylatoxin. Nature (1991) 349: 614–617.
  • HAVILAND DL, MCCOY RL, WHITEHEAD WT: Cellular expression of the C5a anaphylatoxin receptor (C5aR): demonstration of C5aR on nonmyeloid cells of the liver and lung. J. Immunol. (1995) 154:1861–1869.
  • MULLERLADNER U, JONES JL, WETSEL RA, GAY S, RAINE CS, BARNUM SRA: Enhanced expression of chemotactic receptors in multiple sclerosis lesions. J. Neurol. Sci. (1996) 144:135–141.
  • VALAZQUEZ P, CRIBBS DH, POULOS TL, TENNER AJ: Aspartate residue 7 in amyloid beta protein is critical for classical complement pathway activation: implica-tions for Alzheimer's disease pathogenesis. Nature Med. (1997) 3:77–79.
  • GASQUE P, SINGHRAO S K, NEAL J W, GOTZE O, MORGAN BP: Expression of the receptor for comple-ment C5a (CD88) is up-regulated on reactive astrocytes,, microglia and endothelial cells in the inflamed human central nervous system. Am. J. Pathol (1997) 150:31–41.
  • MORGAN EL: Modulation of the immune response by anaphylatoxins. Complement (1986) 3:128–136.
  • TEMPERO RM, HOLLINGSWORTH MA, BURDICK ET et al.: Molecular adjuvant effects of a conformationally biased agonist of human C5a anaphylatoxin. J. Immunol (1996) 158:1377–1382.
  • ••Effects of a C5a agonist demonstrating in vivo immuno-adjuvant effects.
  • MORELLI A, LARREGINA A, CHULUYAN I, KOLKOWSKI E, FAINBOIM L: Expression and modulation of C5a receptor (CD88) on skin dendritic cells. Chemotactic effect of C5a on skin migratory dendritic cells. Immunology (1996) 89:126–134.
  • NATAF S, DAVOUST N, AMES RS, BARNUM SR: Human T cells express the C5a receptor and are chemoattracted to C5a. j Immunol. (1999) 162:4018–4023.
  • STEVENS, JH, O'HANLEY P, SHAPIRO JM et al: Effects of anti-05a antibodies on the adult respiratory distress syndrome in septic primates. J. Clin. Invest. (1986) 77:1812–1816.
  • MORGAN EL, EMBER JA, SANDERSON SD et al.: Anti-05a receptor antibodies. Characterization of neutralizing antibodies specific for a peptide, C5aR-(9–29), derived from the predicted amino-terminal sequence of the human C5a receptor. J Immunol (1993) 151:377–388.
  • WEISMAN HF, BARTOW T, LEPPO MK et al.: Soluble human complement receptor Type 1: in vivo inhibitor of complement suppressing post-ischemic myocar-dial inflammation and necrosis. Science (1990) 249:146–151.
  • ••Inhibition of complement activation reduces myocardialreperfusion injury.
  • HUANG J, KIM LJ, MEALEY R et al.: Neuronal protection in stroke by an sLex-glycosylated complement inhibi-tory protein. Science (1999) 285:595–599.
  • MOSSAKOWSKA D, DODD I, PINDAR W, SMITH RA: Structure-activity relationships within the N-terminal short consensus repeats (SCR) of human CR1 (C3b/C4b receptor, CD35): SCR 3 plays a critical role in inhibition of the classical and alternative pathways of complement activation. Eur. J. Immunol. (1999) 29:1955–1965.
  • MOLLISON KW, MANDECKI W, ZUIDERWEG ER et al.: Identification of receptor-binding residues in the inflammatory complement protein C5a by site-directed mutagenesis. Proc. Natl. Acad. Sci. USA (1989) 86:292–296.
  • PELLAS TC, BOYAR W, OOSTRUM VAN J et al.: Novel C5a receptor antagonists regulate neutrophils functions in vitro and in vivo. J. Immunol. (1998) 160:5616–5621.
  • HELLER T, HENNECKE M, BAUMANN U et al.: Selection of a C5a receptor antagonist from phage libraries attenu-ating the inflammatory response in immune complex disease and ischemia/reperfusion injury. J. Immunol (1999) 163:985–995.
  • WONG AK, TAYLOR SM, FAIRLIE DP: Development ofC5a receptor antagonists. Invest. Drugs (1999) 2:686–693.
  • CHENOWETH DE, HUGLI TE : Human C5a and C5a analogs as probes of the neutrophil C5a receptor. Mol. Immunol. (1980) 17:151–161.
  • SICILIANO SJ, ROLLINS, TE, DEMARTINO, J: Two-sitebinding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors. Proc. Natl. Acad. Sci. USA (1994) 91:1214–1218.
  • ROLLINS TE, SICILIANO S, SPRINGER MS: Solubilizationof the functional C5a receptor from human polymor-phonuclear leukocytes. J. Biol. Chem. (1988) 263:520–526.
  • KAWAI M, QUINCY DA, LANE B, MOLLISON KW, LULY JR,CARTER GW: Identification and synthesis of a receptor binding site of human anaphylatoxin C5a. J. Med. Chem. (1991) 34:2068–2071.
  • OR YS, CLARK RF, LANE B, MOLLISON KW, CARTER GW,LULY JR: Improvements in the minimum binding sequence of C5a: examination of His-67. J. Med. Chem. (1992) 35:402–406.
  • DRAPEAU G, BROCHU S, GODIN D, LEVESQUE L, RIOUXF, MARCEAU F: Synthetic C5a receptor agonists. Pharmacology, metabolism and in vivo cardiovascular and hematologic effects. Biochem. Pharmacol. (1993) 45:1289–1299.
  • EMBER JA, SANDERSON SD, TAYLOR SM, KAWAHARA M,HUGLI TE: Biologic activity of synthetic analogues of C5a anaphylatoxin. J. Immunol. (1992) 148:3165–3173.
  • SANDERSON SD, KIRNARSKY L, SHERMAN SA, EMBER JA,FINCH AM, TAYLOR SM: Decapeptide agonists of human C5a: the relationship between conformation and spasmogenic and platelet aggregatory activities. J. Merl. Chem. (1994) 37:3171–3180.
  • SANDERSON SD, KIRNARSKY L, SHERMAN SA et al: Decapeptide agonists of human C5a: the relationship between conformation and neutrophil response. J. Merl. Chem. (1995) 38:3669–3675.
  • KOHL J, LUBBERS B, KLOS A, BAUTSCH W, CASARETTO M,: Evaluation of the C-terminal C5a effector site with short synthetic C5a analog peptides. Eur. J. Immunol. (1993) 23:646–652.
  • KONTEATIS ZD, SICILIANO SJ, VAN RG et al.: Develop-ment of C5a receptor antagonists. Differential loss of functional responses. J. Immunol (1994) 153:4200–4205.
  • ••First report of a small molecule C5a receptor antagonistderived from C5a.
  • WONG AK, FINCH AM, PIERONS G, CRAIK D, TAYLOR SM, FAIRLIE, DP: Molecular probes for G-protein coupled receptors. Conformationally constrained antagonists derived from the C-terminus of human plasma protein C5a. J. Med. Chem. (1998) 41:3417–3425.
  • ••Cyclisation of hexapeptide C5a antagonist leads to increasedantagonist affinity and potency.
  • SHORT AJ, PACZKOWSKI NJ, VOGEN SM, SANDERSON SD, TAYLOR SM: Response-selective C5a agonists: differential, effects on neutropenia and hypotension in the rat. Br. J. Pharmacol. (1999) 128:511–514.
  • FINCH AM, WONG AK, PACZKOWSKI NJ et al: Low molecular weight peptidic and cyclic antagonists of the C5a receptor. J. Med. Chem. (1999) 42:1965–1974.
  • VOGEN SM, PRAKASH O, KIRNARSKY L, SANDERSON SD,SHERMAN SA: NMR analysis of a potent decapeptide agonist of human C5a anaphylatoxin. J. PepL Res. (1998) 51:226–34.
  • SHORT A, WONG AK, FINCH AM et al.: Effects of a newC5a receptor antagonist on C5a- and endotoxin-induced neutropenia in the rat. Br. J. Pharmacol. (1999) 126:551–554.
  • MIZUNO M, NISHIKAWA K, OKADA N, MATSUO S, ITO K,OKADA H: Inhibition of a membrane complement regulatory protein by a monoclonal antibody induces acute lethal shock in rats primed with lipopolysaccha-ride. J. Immunol. (1999) 162:5477–5482.
  • HENSENS OD, BORRIS RP, KOUPAL LR et al.: L-156,602, aC5a antagonist with a novel cyclic hexadepsipeptide structure from Streptomyces sp. MA6348. Fermenta-tion, isolation and structure determination. J. Antibi-otics (Tokyo) (1991) 44:249–254.
  • LANZA TJ, DURETTE PL, ROLLINS T et al.: Substituted4,6-diaminoquinolines as inhibitors of C5a receptor binding. J. Merl. Chem. (1992) 35:252–258.
  • TSUJI RF, MAGAE J, NAGAI K, YAMASAKI M: Effects ofL-156,602, a C5a receptor antagonist, on mouse experi-mental models of inflammation. Biosci. Biotech. Biochem. (1992) 56:2034–2036.
  • SAHU A, KAY BK, LAMBRIS JD: Inhibition of humancomplement by a C3-binding peptide isolated from a phage-displayed random peptide library. J. Immunol. (1996) 157:884–891.
  • FIANE AE, MOLLNES TE, VIDEM V et al.: Compstatin, apeptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. Xenotransplantation (1999) 6:52–65.
  • NILSSON B, LARSSON R, HONG J et al.: Compstatininhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Blood (1998) 92:1661–1667.
  • WHITEHOUSE MW, FAIRLIE, DP: Anti-inflammatory activity of a holothurian (sea cucumber) food supple-ment in rats. Inflammopharmacology (1994) 2:411–417.
  • SMEDEGARD G, CUI LX, HUGLI TE: Endotoxin-inducedshock in the rat. A role for C5a. Am. J. Pathol. (1989) 135:489–497.
  • CZERMAK BJ, SARMA V, PIERSON CL et al.: Protectiveeffects of C5a blockade in sepsis. Nature Med (1999) 5:788–792.
  • YASOJIMA K, SCHWAB C, MCGEER EG, MCGEER PL: Human, heart generates complement proteins that are upregulated and activated after myocardial infarction. Circ. Res. (1998) 83:860–869.
  • AMSTERDAM EA, STAHL GL, PAN HL, RENDIG SV, FLETCHER MP, LONGHURST JC: Limitation of reperfu-sion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am. J. Physiol. (1995) 268(1Pt2):H448–457.
  • BINGEL M, ARNDT W, SCHULZE M et al.: Comparative study of C5a plasma levels with different hemodialysis membranes using an enzyme-linked immunosorbent assay. Nephron (1989) 51:320–324.
  • BERGH K, IVERSEN 0J, LYSVAND, H: Surprisingly high levels of anaphylatoxin C5a des Arg are extractable from psoriatic scales. Arch. Dermatol. Res. (1993) 285: 131–134.
  • HELLER T, HENNECKE M, BAUMANN U et al: Selection of a C5a receptor antagonist from phage libraries attenu-ating the inflammatory response in immune complex disease and ischemia/reperfusion injury. J. Immunol. (1999) 163:985–994.
  • JOSE PJ, MOSS IK, MAINI RN, WILLIAMS TJ: Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. Ann. Rheum. Dis. (1990) 49:747–752.
  • ROLLINS SA, MATIS LA, SPRINGHORN JP, SETTER E, WOLFF DW: Monoclonal antibodies directed against human C5 and C8 block complement-mediated damage of xenogeneic cells and organs. Transplanta-tion (1995) 60:1284–1292.
  • MULLER TF, KRAUS M, NEUMANN C, LANGE HRA: Detection of renal allograft rejection by complement components C5a and TCC in plasma and urine. J. Lab. Olin. Med. (1997) 129:62–71.

Websites

  • www.AlexionPharm.com/products/index.cfm (March 2000).
  • www.avantimmune.com/technology.htm#COMPLEMENT INHIBITORS (March 2000).
  • www.adprotech.co.uk/news.htm#Membrane-targeted (March 2000).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.